for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Advaxis, Inc.

ADXS.OQ

Latest Trade

0.39USD

Change

-0.12(-23.17%)

Volume

4,058,840

Today's Range

0.38

 - 

0.53

52 Week Range

0.21

 - 

10.79

As of on the NASDAQ ∙ Minimum 15 minute delay

Latest Developments

Advaxis Inc - Received Written Notice From Staff Of Listing Qualifications Department Of Nasdaq Stock Market

Sept 13 (Reuters) - Advaxis Inc <ADXS.O>::ADVAXIS INC - RECEIVED WRITTEN NOTICE FROM STAFF OF LISTING QUALIFICATIONS DEPARTMENT OF NASDAQ STOCK MARKET.ADVAXIS INC - NASDAQ INDICATED THAT ADVAXIS WAS NOT IN COMPLIANCE WITH A NASDAQ LISTING RULE.

Advaxis Reports Qtrly Loss Per Share $1

Sept 9 (Reuters) - Advaxis Inc <ADXS.O>::ADVAXIS REPORTS FISCAL THIRD QUARTER 2019 FINANCIAL RESULTS AND PROVIDES PIPELINE UPDATE.ADVAXIS INC - AS OF JULY 31, CO HAD APPROXIMATELY $41.8 MILLION IN CASH & CASH EQUIVALENTS.ADVAXIS INC - CO BELIEVES CAPITAL IS SUFFICIENT TO FUND OBLIGATIONS UNTIL AT LEAST SEPTEMBER 2020.ADVAXIS INC QTRLY REVENUE $6000 VERSUS $1.1 MILLION.ADVAXIS INC QTRLY LOSS PER SHARE $1.

Advaxis Inc Files For Offering Of Up To 11.8 Million Shares Of Common Stock And Warrants To Purchase Up To 8.9 Million Shares Of Common Stock

July 22 (Reuters) - Advaxis Inc <ADXS.O>::ADVAXIS INC FILES FOR OFFERING OF UP TO 11.8 MILLION SHARES OF COMMON STOCK AND WARRANTS TO PURCHASE UP TO 8.9 MILLION SHARES OF COMMON STOCK.

Advaxis says New Immune Data From Adxs-Neo Phase 1 Study Support Clinical Potential For Neoantigen-Directed Immunotherapies

July 15 (Reuters) - Advaxis Inc <ADXS.O>::NEW IMMUNE DATA FROM ONGOING ADXS-NEO PHASE 1 STUDY SUPPORT CLINICAL POTENTIAL FOR NEOANTIGEN-DIRECTED IMMUNOTHERAPIES.ADVAXIS INC - CD8+ T CELL REACTIVITY AGAINST 90% OF PERSONALIZED NEOANTIGEN TARGETS CONFIRMED IN FIRST OF TWO PATIENTS.ADVAXIS INC - TO DATE, DOSING OF ADXS-NEO AT 1X10(8) COLONY FORMING UNITS (CFU) HAS BEEN WELL-TOLERATED IN TWO PATIENTS.ADVAXIS INC - CONTINUE TO ENROLL PATIENTS IN PHASE 1 STUDY FOR ADXS-NEO.ADVAXIS INC - LOOK FORWARD TO STARTING PART B WITH ADXS-NEO IN COMBINATION WITH CHECKPOINT INHIBITOR LATER THIS YEAR.

Advaxis Files Preliminary Prospectus Related To Offering Of Up To $17.25 Mln Shares

July 2 (Reuters) - Advaxis Inc <ADXS.O>::ADVAXIS INC FILES PRELIMINARY PROSPECTUS RELATED TO OFFERING OF UP TO $17.25 MILLION SHARES OF COMMON STOCK AND PRE-FUNDED WARRANTS - SEC FILING.

Advaxis Posts Q2 Loss Per Share Of $1.59

June 10 (Reuters) - Advaxis Inc <ADXS.O>::ADVAXIS REPORTS SECOND QUARTER FISCAL 2019 FINANCIAL RESULTS AND PROVIDES PIPELINE UPDATE.Q2 LOSS PER SHARE $1.59.Q2 REVENUE $1.2 MILLION VERSUS $1.7 MILLION.AS OF APRIL 30, 2019, ADVAXIS HAD CASH AND CASH EQUIVALENTS OF $33.7 MILLION.

FDA Lifts Partial Clinical Hold On Phase 3 Aim2cerv Study Of Axalimogene Filolisbac

May 15 (Reuters) - Advaxis Inc <ADXS.O>::FDA LIFTS PARTIAL CLINICAL HOLD ON PHASE 3 AIM2CERV STUDY OF AXALIMOGENE FILOLISBAC.ADVAXIS INC - IN LETTER, FDA ACKNOWLEDGED THAT COMPANY SATISFACTORILY ADDRESSED ALL HOLD QUESTIONS..ADVAXIS - FDA HAS LIFTED PARTIAL CLINICAL HOLD ON AIM2CERV, COMPANY'S PHASE 3 CLINICAL TRIAL OF AXALIMOGENE FILOLISBAC (AXAL).

Advaxis Announces Pricing Of Its Public Offering Of Common Stock

April 3 (Reuters) - Advaxis Inc <ADXS.O>::ADVAXIS ANNOUNCES PRICING OF ITS PUBLIC OFFERING OF COMMON STOCK.ADVAXIS ANNOUNCES PRICING OF ITS PUBLIC OFFERING OF COMMON STOCK.ADVAXIS INC - OFFERING AT A PRICE TO PUBLIC OF $4.00 PER SHARE.

Advaxis Announces Proposed Public Offering Of Common Stock

April 2 (Reuters) - Advaxis Inc <ADXS.O>::ADVAXIS, INC. ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK.ADVAXIS - INTENDS TO USE NET PROCEEDS FROM OFFERING TO FUND ITS CONTINUED RESEARCH AND DEVELOPMENT INITIATIVES IN CONNECTION WITH ITS PRODUCT PIPELINE.

Advaxis Announces 1 For 15 Reverse Stock Split

March 28 (Reuters) - Advaxis Inc <ADXS.O>::ADVAXIS ANNOUNCES REVERSE STOCK SPLIT.ANNOUNCES 1 FOR 15 REVERSE STOCK SPLIT.BEGINNING ON MARCH 29, 2019, ADVAXIS' COMMON STOCK WILL TRADE ON NASDAQ GLOBAL SELECT MARKET ON A REVERSE SPLIT-ADJUSTED BASIS.1-FOR-15 REVERSE STOCK SPLIT OF ITS COMMON STOCK WILL BECOME EFFECTIVE, MARCH 29, 2019.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up